Elevation Oncology downgraded as it halts lead asset on disappointing trials
Investing.com -- Wall Street cut rating on Elevation Oncology Inc (NASDAQ:ELEV) after the company announced it will discontinue development of its lead asset, EO-3021, due to disappointing efficacy in a Phase 1 trial. Analysts now see limited near-term catalysts, with Elevation pivoting to its HER3-targeted ADC, EO-1022, which is still in preclinical development.